



Bortz, E., Wu, T-T., Patel, P. H., Whitelegge, J. P., & Sun, R. (2018). Proteomics of Bronchoalveolar Lavage Fluid Reveals a Lung Oxidative Stress Response in Murine Herpesvirus-68 Infection. *Viruses*, 10(12), [670]. <https://doi.org/10.3390/v10120670>

Publisher's PDF, also known as Version of record

License (if available):
CC BY

Link to published version (if available):
[10.3390/v10120670](https://doi.org/10.3390/v10120670)

[Link to publication record in Explore Bristol Research](#)
PDF-document

This is the final published version of the article (version of record). It first appeared online via MDPI at <https://www.mdpi.com/1999-4915/10/12/670>. Please refer to any applicable terms of use of the publisher.

University of Bristol - Explore Bristol Research

General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: <http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/>

Article

Proteomics of Bronchoalveolar Lavage Fluid Reveals a Lung Oxidative Stress Response in Murine Herpesvirus-68 Infection

Eric Bortz ^{1,*}, Ting-Ting Wu ², Parthive Patel ³, Julian P. Whitelegge ⁴ and Ren Sun ^{2,*}¹ Department of Biological Sciences, University of Alaska Anchorage, Anchorage, AK 99508, USA² Department of Molecular & Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA; twu@mednet.ucla.edu³ Center for Molecular Biology and German Cancer Research Center (DKFZ), University of Heidelberg (ZMBH), 69120 Heidelberg, Germany; p.patel@dkfz-heidelberg.de⁴ The Pasarow Mass Spectrometry Laboratory & the Jane and Terry Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA; jpw@chem.ucla.edu

* Correspondence: ebortz@alaska.edu (E.B.); rsun@mednet.ucla.edu (R.S.); Tel.: +1-907-786-4858 (E.B.)

Received: 28 October 2018; Accepted: 20 November 2018; Published: 27 November 2018



Abstract: Murine herpesvirus-68 (MHV-68) productively infects mouse lungs, exhibiting a complex pathology characteristic of both acute viral infections and chronic respiratory diseases. We sought to discover proteins differentially expressed in bronchoalveolar lavage (BAL) from mice infected with MHV-68. Mice were infected intranasally with MHV-68. After nine days, as the lytic phase of infection resolved, differential BAL proteins were identified by two-dimensional (2D) electrophoresis and mass spectrometry. Of 23 unique proteins, acute phase proteins, vitamin A transport, and oxidative stress response factors Pdx6 and EC-SOD (Sod3) were enriched. Correspondingly, iNOS2 was induced in lung tissue by seven days post-infection. Oxidative stress was partly a direct result of MHV-68 infection, as reactive oxygen species (ROS) were induced in cultured murine NIH3T3 fibroblasts and human lung A549 cells infected with MHV-68. Finally, mice infected with a recombinant MHV-68 co-expressing inflammatory cytokine murine interleukin 6 (IL6) showed exacerbated oxidative stress and soluble type I collagen characteristic of tissue recovery. Thus, oxidative stress appears to be a salient feature of MHV-68 pathogenesis, in part caused by lytic replication of the virus and IL6. Proteins and small molecules in lung oxidative stress networks therefore may provide new therapeutic targets to ameliorate respiratory virus infections.

Keywords: murine herpesvirus-68; MHV-68; bronchoalveolar lavage fluid; BAL; proteomics; oxidative stress

1. Introduction

Respiratory virus infections have the potential to cause significant lung pathology including acute respiratory distress syndrome (ARDS). In addition to the continual burden of disease from respiratory viruses such as influenza types A and B, respiratory syncytial virus (RSV), parainfluenza viruses, adenovirus, recently emerged coronaviruses responsible for Middle East (MERS-CoV) and severe acute (SARS-CoV) respiratory syndromes, H5N1 and H7N9 pathogenic avian influenza viruses, pandemic swine-origin (H1N1) influenza, and human metapneumovirus target the human lungs [1–7]. Co-morbid, underlying pulmonary medical conditions including asthma, chronic obstructive pulmonary disease (COPD), and tuberculosis (TB) are associated with severe respiratory virus infections [8–11]. Moreover, chronic pulmonary diseases such as asthma, COPD, and

idiopathic pulmonary fibrosis (IPF) might have an infectious viral component to their onset and/or pathogenesis. The gammaherpesviruses Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) and Epstein-Barr virus (EBV) have been detected in the lung tissue of patients with IPF and acquired immune deficiency syndrome (AIDS)-related lymphocytic interstitial pneumonias [12–14]. In contrast, a murine gammaherpesvirus is protective in mice challenged with lethal influenza A virus, suggesting immunomodulatory roles for gammaherpesviruses in the pathogenesis of lung infections [14]. Thus, the application of new genomics technologies for understanding respiratory virus infections under isogenic host conditions might yield deeper insight into the pathological changes that occur in virus infection of the mammalian lung, and provide targets for diagnostic biomarkers or therapeutic intervention.

Murine gammaherpesvirus-68 (MHV-68) infects the lungs of wild and laboratory mice, productively infecting type I and II alveolar epithelial cells, macrophages, and dendritic cells (DCs) [15,16]. MHV-68 exhibits characteristics of both acute and chronic respiratory pathogens. Even though MHV-68 can inhibit type I interferon secretion by DCs [17], the lungs of mice infected by the virus eventually exhibit discernable pathology, including usual interstitial pneumonia (UIP) with diffuse alveolar damage (DAD), and infiltration of inflammatory cells [16,18,19]. MHV-68 infection induces pro-inflammatory chemokines including MCP-1, MIP-1a, MIP-1b, IP-10 and RANTES [20] in the lung, and interleukin-6 (IL6) and type II interferon (IFN- γ) in the draining (mediastinal) lymph nodes [21]. Acute infection is resolved and lytic replication of the virus is cleared from the lungs in a CD8⁺ cytotoxic T-lymphocyte (CTL-) and type I alpha/beta-interferon receptor (IFNAR)-dependent manner [22,23]. Clearance also requires CD80/CD86 antigen presentation [24], IFN- γ [25], and some degree of CD4⁺ T-cell help reliant on PKC θ [26]. However, as gammaherpesvirus infection progresses into latency, MHV-68 DNA remains detectable in the lung parenchyma, recapitulating a chronic disease characterized by increased interstitial collagen deposition, immune deregulation, and fibroblast proliferative events similar to those thought to occur early in the development of idiopathic pulmonary fibrosis (IPF). This chronic pathology phenotype is more clearly observed under experimental conditions where the lungs have been insulted prior to infection by an agent that induces pulmonary fibrosis [27], such as fluorescein isothiocyanate (FITC), or in mice deficient in immune responses, such as interferon gamma receptor-null mice [15].

The pro-inflammatory cytokine IL6 is thought to be involved in the host response to respiratory infections. IL6 is upregulated in ARDS caused by bacterial pneumonias in human patients [28], and in LPS-treated human lung cells infected with RSV [29]. While no differences in viral life cycle, cytokine profiles, nor cytotoxic T-cell responses were observed in MHV-68 infection of IL6-deficient mice, IL6 does appear to regulate natural killer (NK) cells responding to MHV-68 infection [30]. Interestingly, KSHV also encodes a viral homologue of IL6 (vIL6) with distinct signaling activity during lytic infection [31,32]. To study the role of exogenous expression of this cytokine in gammaherpesvirus infection of the lung, we constructed a recombinant MHV-68 virus expressing murine IL6.

Proteomics analysis of bronchoalveolar lavage (BAL) fluid has emerged as a new approach to understand pathophysiological events occurring in acute, infectious, malignant or chronic obstructive lung diseases, both in human patients and animal models [33,34]. BAL is a rich source of information about lung cytokine and chemokine responses, inflammatory proteins, and immune cells present or infiltrating into the alveolar lumen. In proteomics studies, proteins isolated from BAL fluid have been typically analyzed by isoelectric focusing followed by two-dimensional electrophoresis (IEF/2DE), or by multidimensional protein identification technology (MudPIT), allowing for the identification of differentially-expressed proteins secreted or released via pathological processes into the alveolar lumen. These studies have begun to add a new dimension into the characterization of human or mouse physiological responses to acute lung injury (ALI) [33], acute respiratory distress syndrome (ARDS) [35,36], and diffuse interstitial lung diseases including IPF [37], COPD [38], and oxidative or toxicological damage to the lung [39,40]. In animal models of infectious diseases, BAL has revealed lung cytokine and chemokine profiles and immune cell populations in response to virus infections [15,20,41].

For a monkeypox virus infection model in macaques [42] and three pathogens in mouse infection models, RSV [43], *Staphylococcus aureus* [44,45], and *Klebsiella pneumoniae* [46], proteomics analyses of BAL have identified inflammatory proteins and revealed commonalities in infectious pulmonary pathophysiology. Analysis of mouse BAL by IEF/2DE showed a suppression of antioxidant and oxidative stress proteins during RSV infection [43]. However, no analysis using differential IEF/2DE proteomics in MHV-68 infection of the mouse lung have been published to date.

As many human viruses infect the lung, understanding the proteins present in BAL using MHV-68 as a model may uncover novel aspects of the mammalian host's response to pulmonary viral infections. Using proteomics, we have identified mouse BAL proteins that are differentially up-regulated by virus infection and overexpression of a immunomodulatory cytokine (IL6). Proteins involved in the acute phase response, oxidative stress responses, and vitamin A signaling were salient in the MHV-68 infected lung. Interestingly, these proteins are induced by nine days post-infection (d.p.i.), as the initial phase of MHV-68 infection resolves and lytic replicating virus is cleared from the lungs by T-cell mediated host responses [20,23]. The experimental protocol herein demonstrates the feasibility of differential BAL proteomics to characterize less abundant, highly regulated host factors in BAL fluid.

2. Materials and Methods

2.1. Viruses and cell Cultures

Wild-type (WT) MHV-68, MHV68/IL6, and red fluorescent protein (RFP)/MHV-68 viruses in this study were all titrated by plaque overlay assay on BHK21 cells as previously described [47,48]. Recombinant viruses were generated by co-transfection of MHV-68 genomic DNA and a PCR-generated cDNA encoding the gene to be inserted flanked by MHV-68 sequences corresponding to the MHV-68 genome. MHV68/IL6 virus was generated by homologous insertion of murine cDNA encoding interleukin-6 (IL6) driven by a cytomegalovirus (CMV) immediate early (IE) promoter–enhancer into an intergenic locus near the 5' end of the MHV-68 genome [49]. The RFP/MHV-68 virus was generated in a similar manner whereby a cDNA encoding RFP driven by CMV IE promoter–enhancer was inserted into the ORF28 locus. The ORF28 gene is dispensable for infection of cultured cells and *Mus musculus* models of MHV-68 infection [50]. Recombinant viruses were selected by plaque-purification, viral DNA was purified and screened for cDNA insertion into expected loci by PCR and restriction fragment digestion followed by Southern blotting, as has been described [48,49,51]. During lytic infection in NIH3T3 cells, expression of IL6 from the MHV68/IL6 virus was confirmed by Western blotting and ELISA; for RFP/MHV-68, expression of RFP was observed by epifluorescent microscopy. To probe for reactive oxygen species (ROS), murine NIH3T3 or human A549 cells were infected with RFP/MHV-68 at a multiplicity of infection (m.o.i) of 1 or 5 and at 4 h or 20 h post-infection (h.p.i.), cells were rinsed in cold $1 \times$ phosphate-buffered saline (PBS), incubated for 5 min at 37 °C in the dark in $1 \times$ PBS containing 5 μ M 5/6-carboxy-2',7'-difluorodihydrofluorescein diacetate (H_2DF_2DA), a compound that exhibits superior photostability compared to other fluorescein derivatives (Invitrogen, Carlsbad, CA, USA), washed in $1 \times$ PBS, and then imaged in an epifluorescent microscope. ROS-inducing compounds H_2O_2 or paraquat (10 μ M) were employed as positive controls for H_2DF_2DA fluorescence. For examining ROS effects on viral titer, NIH3T3 cells were infected with RFP/MHV-68 (m.o.i. = 0.25) in the absence or presence of 1 mM soluble glutathione (GSH) or 2–25 μ M paraquat in media. After 20 h, culture supernatants were diluted 1/2, 1/10, or 1/100, used to re-infect fresh NIH3T3 cells, and RFP fluorescence observed 20 h.p.i. by epifluorescence microscopy using a Zeiss Axiovert epifluorescence microscope (C. Zeiss AG, Oberkochen, Germany).

2.2. Mouse Infections with MHV-68 and MHV68/IL6 Viruses

All in vivo mouse experiments were conducted at the University of California, Los Angeles (UCLA) in a dedicated animal facility under approved protocols, following ethical guidelines for laboratory animals in research by the Animal Research Committee at the University of California,

Los Angeles (IACUC protocol number # 1999-058; Approved 1 Jan. 1999; renewed 2004–2006). Twelve-week old male C57/BJ6 mice (Charles River Laboratories, Wilmington, MA, USA) were anesthetized with 0.1 mL (100 mg/kg) ketamine by intraperitoneal (i.p.) injection, and then inoculated with 20 μ L DMEM (6 mice) or infected intranasally (i.n.) with 5×10^5 pfu of WT MHV-68 (6 mice) or MHV68/IL6 (6 mice) virus diluted in 20 μ L DMEM. Mice in each experimental group were housed separately until sacrifice at 6 or 9 d.p.i., when at each timepoint, 3 mice in each experimental group were anesthetized and sacrificed under anesthesia by i.p. injection of 0.1 mL ketamine. Mice were subsequently dissected for bronchoalveolar lavage (BAL) thrice with 1.4 mL sterile $1 \times$ PBS via a rounded 21G syringe inserted by tracheotomy and affixed with suturing thread. Separately, 2 more mice in the DMEM and in each infected group were sacrificed at 7 d.p.i. for whole-lung harvest with snap-freezing of tissue in liquid N₂, and determination of viral titer and gene expression as described [47,49]. BAL fluid was centrifuged immediately ($2000 \times g$, 15 min., 4 °C) to separate soluble, supernatant phases and the cell/debris pellet. Supernatants were kept at -80 °C until processing. Cell pellets were resuspended in 50 μ L 0.5% FBS DMEM containing 1 mM EDTA, and monocytes in 5 μ L aliquots were counted by trypan blue exclusion test with a hemocytometer. Aliquots of cell fractions (5 μ L) were also analyzed by thin smear on poly-lysine coated glass slides followed by fixation and eosin/hematoxylin staining with Hema3 (Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer's instructions, and light microscopy (Olympus Corp., Tokyo, Japan).

2.3. BAL Fluid Processing

Aliquots of BAL fluid supernatants were used for Sircol collagen assay, viral DNA detection by quantitative PCR, and protein detection by Western blotting. For each experimental infection (MHV-68 and MHV68/IL6), one of the three BAL samples containing significant numbers of erythrocytes was deselected. To have sufficient protein for resolution by proteomics methods, the remaining 2 BAL fluid supernatants were pooled for each experimental condition, precipitated in 95% acetone at -20 °C for 2 h, centrifuged (4 °C, 15 min, $20,000 \times g$), and then resuspended in binding buffer. To reduce abundant immunoglobulins and albumin, Aurum column binding and elution (Bio-Rad, Hercules, CA, USA) was done according to the manufacturer's instructions. Eluents were re-concentrated and desalted by 4:1 acetone (95%, ice-cold) precipitation for 2 h, centrifuged (4 °C, 15 min, $20,000 \times g$), and resuspended in isoelectric focusing (IEF) buffer. A Bradford assay was used to quantify protein concentration prior to and post-processing [52], and SDS-PAGE with SYPRO-Ruby staining was used to observe depletion of abundant albumin bands.

2.4. Sircol Collagen Assay

For lung tissue collagen assay, 0.05 g lung tissue was homogenized in 0.5 M acetic acid (1 mL) containing 7.5 mg pepsin, and rotated for 24 h at 4 °C. Samples were briefly centrifuged to pellet debris, and 100 μ L of each supernatant was assayed for collagen by Sircol assay as described by the manufacturer (BioColor Ltd., Carrickfergus Belfast, UK). For measuring soluble collagen in BAL fluid, aliquots of 25 μ L were subjected to Sircol assay. Collagen concentration was determined by absorbance at 540 nm in a spectrophotometer and titration according to standard curves generated for lung tissue and BAL fluid.

2.5. Catalase Assay and Immunoblotting

NIH3T3 cells were lysed in passive lysis buffer and protein content was normalized by a Bradford assay as described previously [52], and lysates were subjected to a catalase activity assay (Sigma, St. Louis, MO, USA) according to the manufacturer's instructions. A standard curve was generated with controlled quantities of H₂O₂. H₂O₂ treatment for 24 h yielded only a minimal induction of catalase activity in this assay. For Western blots, protein lysates separated by SDS-PAGE were Western blotted and probed with specific polyclonal anti-ORF65/M9 anti-sera or anti-catalase antibody

(Calbiochem, San Diego, CA, USA) with HRP-linked secondary and electrochemiluminescent detection as described [48].

2.6. PCR

For quantitative RT-PCR, total RNA was isolated from mouse lungs 7 d.p.i. and reverse transcribed into cDNA as described [47,49]. Primers to specific murine genes (described in Supporting Information Table S2) were used to amplify transcript cDNA and relative transcript copies determined by the $\Delta\Delta C_T$ method with an actin internal control by SyberGreen (Applied Biosystems, Carlsbad, CA, USA) real-time detection on a LightCycler thermocycler (Roche, Indianapolis, IN, USA). Significance of relative gene expression was determined by an unpaired, 2-tailed *t*-test. Viral DNA representing viral genome copy number was determined for each mouse BAL sample by qPCR with primers specific to MHV-68 genomic ORF65/M9 or ORF57 loci as previously described [48,51].

2.7. IEF, 2D-PAGE, Spot Mapping and Densitometry

Eluted BAL proteins (300 μ L) were resuspended in IEF buffer containing ampholytes covering the pH 3–10 range (Bio-Rad, Hercules, CA, USA). Samples passively loaded on rehydrated, immobilized 11 cm nonlinear pH 3–10 gradient IPG strips (Bio-Rad, Hercules, CA, USA) and then focused by *pI* for 18 h ramping over 6 h to a maximum current of 70,000 V-h in a Protean IEF Cell (Bio-Rad, Inc., Hercules, CA, USA). Strips were re-equilibrated for 30' in DTT and then iodoacetamide buffers and proteins separated by mass in a denaturing 8–16% gradient Criterion 2D-PAGE (Bio-Rad, Inc., Hercules, CA, USA). Two-dimensional gels were briefly incubated in 10% methanol/5% acetic acid, rinsed in ddH₂O, and stained for 3 h with SYPRO-Ruby (Invitrogen, Carlsbad, CA, USA). Gels were imaged under UV light and analyzed to identify differentially-expressed protein spots. Proteins resolved in the pH 4–7 range were sufficiently separated for spot mapping across gels using an integrated ProteomeWorks *PD Quest 7.1* imager and software (Bio-Rad, Carlsbad, CA, USA) with manual spot validation. Spots were quantified by peak cross-sectional densitometry using *ImageQuant* (GE Healthcare, Piscataway, NJ, USA), and normalized to an average of oxytocin-receptor (spot 13) and a common major form of eluted albumin (spot 5) relative to gel image background density. A total of 89 abundant differential spots across the three experimental conditions were excised and in-gel digested in Trypsin Gold MS (Promega, Madison, WI, USA), and alkylated peptides were extracted, dried and stored at -80°C as described previously [53] for mass spectrometry identification.

2.8. Mass Spectrometry

Tryptic peptide digests of proteins were separated on a reverse phase column and identified by tandem micro-LC/MS-MS and in some cases, by MALDI-TOF mass spectrometry, with sample handling as described previously [54,55]. BSA (5 pmol) digested in Trypsin Gold was used to generate positive control spectra for LC/MS-MS and MALDI-TOF experiments, respectively. Briefly, MS-MS spectra were captured on an AB Sciex Qstar quadrupole XL hybrid TOF LC/MS-MS (Applied Biosystems, Foster City, CA, USA) with tandem peptide ion fragmentation running in Information Dependent Acquisition (IDA) mode. Peptide and fragment a-, b- and y-series ions spectra were analyzed by *Mascot* software (Matrix Sciences, Boston, MA, USA) with peptide tolerance set at <0.5 Da, MS/MS tolerance <0.8 Da, charge states +1/ +2/ +3/ +4, 1 tryptic digest miss allowed, oxidation of Cys and Met, with peptide identification by search against the predicted mouse proteome at NCBI and EBI reference databases. From tryptic digests of excised spots, 44 yielded peptide data identifying 23 unique proteins. Positive identification cutoffs were determined on a case-by-case basis with expectation scores $<10^{-2}$ ($p < 0.05$, for 20 hits), or $p < 0.1$, for 3 hits, considering multiple peptide hits and supporting MALDI-TOF data in assignment. Another 7 spots did not meet a significance cutoff or poorly matched predicted *pI* and MW, including annexin A5, hemoglobin fragment, triose phosphate isomerase, matrix metalloproteinase 8, serpin b 3d, and collagens I and VI ($p > 0.10$).

For MALDI-TOF, aliquots of peptide digests were mixed with 200× proportion of α -cyano FHSA matrix dissolved in 70% acetonitrile and 0.1% TFA and spotted with laser ionization and data capture with a low mass gate (500 Da) on an AB Sciex Voyager MALDI-TOF running *PD Quest* software (Applied Biosystems, Foster City, CA, USA). MALDI peptide data were searched against the mouse proteome using *Aldente* software [56], with predicted *pI* and molecular mass data estimated from 2D-PAGE spots.


2.9. Bioinformatics Analyses

Functional enrichment among the set of proteins discovered in enriched BAL fluid was analyzed by *Ingenuity Pathways Analysis* (IPA 7.6, Ingenuity Systems Corp., Redwood, CA, USA) as described [57]; IPA categories were tested for significance by a Benjamini–Hochberg test for false discovery [58]. BAL protein functions were also analyzed by Database for Annotation, Visualization, and Integrated Discovery (DAVID) algorithms [59] to assess significant Gene Ontology (GO), InterPro (IPR), and Protein Information Resource (SP_PIR) annotations. A subnetwork of oxidative stress-associated molecules was discovered and extracted using IPA with manual literature curation to construct a network model [60]. Amino acid sequences of human and mouse TNFAIP8 family proteins were obtained from the UniProt database and CLUSTAL multiple sequence alignments performed and formatted using MAFFT FFT-NS-2 v5.731 [61].

3. Results

3.1. Recovery and Characterization of BAL Fluid from Mouse Lungs Infected with MHV-68

An unexpected observation regarding MHV-68 infection of laboratory mice was that MHV-68 infection could exacerbate pulmonary fibrosis [15,27,62–65]. Thus, we also sought to identify proteins induced by MHV-68 infection accompanied by co-expression of murine IL6, a pro-fibrotic cytokine. C57/BJ6 mice were inoculated intranasally (i.n.) with DMEM, or infected with a high titer of WT MHV-68 or a recombinant MHV-68 virus co-expressing murine interleukin-6 (IL6) from a constitutive promoter. To discover secreted or extracellular proteins in virus infection of the mouse lungs, we developed an experimental procedure to analyze the BAL fluid proteome (Figure 1A). At six d.p.i. and nine d.p.i., BAL fluid was collected and analyzed for cells, protein, soluble collagen, and viral DNA content. At six d.p.i., MHV68/IL6 showed significantly more soluble type I collagen in BAL fluid than WT MHV-68 infection; by nine d.p.i., soluble type I collagen was significantly higher in BAL fluid from both WT and MHV68/IL6 infection in comparison to the uninfected control (Figure 1B). Subsequent analysis focused on the nine d.p.i. timepoint, for which soluble type I collagen levels in BAL were similar between the WT virus and MHV68/IL6, and good resolution of proteins by IEF/2DE was achieved. Both protein concentration and mononuclear cellularity in BAL fluid were substantially higher in infected vs. uninfected mice at nine d.p.i., and viral DNA was detected (Figure 1C). MHV-68 viral capsid antigen ORF65/M9 was also present in clarified BAL fluid (Figure S1B). Differences in extracellular virion DNA or DNA from damaged cells in the lung (Figure S1A), which are not a direct measurement of infectious virus titer, were not significant ($p > 0.1$, two-tailed *t*-test). Numbers of BAL mononucleocytes recovered (Figure 1C) was similar to a previous report of phenotypic characterization of mononuclear cell infiltrates (Figure S1C), chemokines and cytokines in MHV-68 infection of the lungs [20].



C. Characteristics of Bronchoalveolar Lavage (BAL) Fluid

Mouse Inoculum	Mice		Protein Recovered		Viral DNA	Cells
	Day	in Pool	BALF (ug)	Eluate (ug)		
DMEM	9	3	375±102	150±16	nd	1.8
MHV-68	9	2	633±197	204±20	1.14	3.1
MHV68/IL-6	9	2	660±124	203±20	0.14	3.8

Figure 1. Analysis of bronchoalveolar lavage (BAL) fluid from murine herpesvirus-68 (MHV-68) infection of the mouse lung. (A) Overview of differential proteomics analysis of proteins induced in BAL by virus infection. Wild-type (WT) MHV-68 or MHV68/IL6 virus infection, BAL fluid processing, protein spot identification, and protein data analysis scheme. BAL fluid processing removed cells, immunoglobulins, excess albumin, and salts, enriching the recovered eluent for less-abundant proteins. (B) Collagen production in MHV-68 infection of the mouse lung is exacerbated by lytic expression of interleukin-6 (IL6). C57/BJ6 mice were mock infected with DMEM or infected intranasally with 5×10^5 pfu of WT MHV-68 or MHV68/IL6 virus. Type I collagen in BAL fluid in MHV-68 and MHV68/IL6 infection was measured at indicated times post-infection by Sircol assay; *p*-value of fold induction estimated from unpaired, 2-tailed *t*-test; error bars represent standard error on the mean (S.E.M.) (C) Characteristics of bronchoalveolar lavage (BAL) fluid. BAL fluid recovered 9 days post-infection (d.p.i.) from C57/BJ6 mice inoculated as above was processed to remove cells, salts, abundant serum proteins and immunoglobulins. Average protein concentration was measured by Bradford assay (± 1 s.d.); eluate exhibited significant differences ($p < 0.05$, unpaired, 2-tailed *t*-test) between MHV-68 and DMEM and MHV68/IL6 and DMEM. Average viral DNA copy number (1×10^5 cp) in BAL in 3 mice for each condition measured by qPCR, and average mononuclear cellularity (1×10^5 cells) measured by trypan blue hemocytometry; differences not significant. IEF = isoelectric focusing.

3.2. Differential Proteomics Analysis of BAL Fluid

Recovered BAL fluid from nine d.p.i. was pooled for each experimental condition (three mice in DMEM, or two mice for WT MHV-68 and MHV68/IL6, respectively), after processing to remove cells and reduce abundant immunoglobulins, albumin, and salts. Reduction of the most abundant proteins in biofluids is a common approach for reducing proteome complexity to enrich less abundant but biologically interesting proteins [66]. Enriched BAL proteins were analyzed by comparative 2D gel electrophoresis (IEF/2DE) display (Figure 2). WT MHV-68 and MHV68/IL6 infection induced a considerably more complex proteome than DMEM-inoculated control mice. Prominent constitutive and differentially-expressed orthologous proteins were mapped and identified by LC/MS-MS and/or MALDI mass spectrometry. We mapped 39 spots in the pH 3–7 range, and identified 23 unique proteins, of which 20 proteins had high significance scores ($p < 0.05$), for example peroxiredoxin 6 (Pdx6, spot #15 in Figure 2; see Figure S2 for example of detailed peptide LC/MS-MS data), and three proteins (A2MP, OxtR, and Tnfaip8l2) had marginal scores ($p < 0.1$) for at least two peptide matches (Supporting Information Table S1). Even though viral ORF65/M9 antigen was detected by Western blot in clarified BAL fluid supernatants (Figure S1), peptides matching MHV-68 virion proteins [53] in enriched BAL fluid data did not reach the significance cutoff ($p > 0.10$). Of the proteins identified, 13 were induced by WT MHV-68 infection (six strongly), and five were markedly upregulated in the context of MHV68/IL6 (Figure 2D). Another four proteins showed a reduced abundance in the context of either virus infection in comparison to DMEM-treated or uninfected control mice (Figure 2D and Table S1).

3.3. Functions of Proteins Induced by MHV-68 in Lungs

While this survey is not a comprehensive list of BAL proteins [34,67], the proteins identified fell into four broad functional groups according to Gene Ontology (GO) classification and the scientific literature (Table 1): (i) acute phase response (APR) and inflammation, (ii) oxidative stress response, (iii) phospholipid metabolism and signaling, and (iv) molecular transport and serum proteins. Most of these proteins have been implicated in inflammation or lung diseases, and many have been identified in proteomics studies of BAL from human patients with ARDS [35,36,68], acute lung diseases [33], IPF [37], or proteomics analysis of serum from patients with severe acute respiratory syndrome (SARS) caused by SARS-coronavirus [69]. The MHV68/IL6 virus induced three antioxidant (thioredoxin-like 4B, peroxiredoxin 2, superoxide dismutase 3) and two acute phase (α 2-macroglobulin, CRABP2) proteins substantially more than WT MHV-68. Accordingly, oxidative stress [70,71] and acute phase responses [72,73] have been shown to be regulated by IL6.




Figure 2. Enriched BAL proteome from mice infected with MHV-68 viruses. Mice were intranasally (i.n.) inoculated with DMEM (A), or infected i.n. with 5×10^5 pfu of WT MHV-68 (B) or MHV68/IL6 virus (C). BAL was collected from mouse lungs 9 d.p.i., pooled, and processed to enrich for less abundant proteins as described in Methods. Eluted BAL proteins were separated by isoelectric focusing followed by 2D-PAGE and SYPRO-Ruby staining. Proteins resolved in the pH 4–7 range were sufficiently separated for spot identification (red numbers), excision, and tryptic digestion for protein identification by MALDI and/or LC/MS-MS. Spots were quantified by densitometry, normalized as described in Methods, and fold induction over orthologous spots in mock (DMEM) treatment is indicated (D). Significant fold induction (>2.0) of MHV68/IL6 over WT MHV-68 specified.

Table 1. Functions of bronchoalveolar lavage proteins identified in MHV-68 infection. Functions of constitutive and differentially-expressed proteins identified by proteomics from BAL fluid from mock (DMEM), MHV-68 infected, and MHV-IL6 infected mice, with selected findings in lung pathophysiology, inflammation and infectious diseases

Spot ^a	BAL Protein Identification	Symbol	GO:Terms ^b	Function	Lung Disease Finding ^c
Acute Phase Response and Inflammation					
1	α 1-acid glycoprotein 1B	A1AG1	0002682	Lipocalin-like immune regulator	APR; TB; IAV
2	α 1-anti-trypsin (serpin A1)	A1AT6	0004867	Serine-type endopeptidase inhibitor	APR; ARDS; COPD; SARS; IAV
3	α 2-macroglobulin	A2MP	0004867	Serum-type endopeptidase inhibitor	APR; ARDS; IPF
11	Haptoglobin	Hp	0004252	Serine-type endopeptidase	APR; SARS
12	IL1 family member 10	IL1f10	0005152	IL1-receptor antagonist	APR; IPF
21	TNF α -induced protein 8-like 2	Tnfaip8l2	0050728	Negative immune regulator	Anti-proliferative
Oxidative Stress Response					
19	Superoxide dismutase 3 [Cu-Zn], ex.	EC-SOD	0006979	Response to oxidative stress	ARDS; NF κ B; antioxidant
10	Glutathione-S-transferase, mu1	GSTM1	0004364	Response to oxidative stress	Antioxidant
14	Peroxiredoxin 2	Pdx2	0006979	Response to oxidative stress	ARDS; SARS; IAV; antioxidant
15	Peroxiredoxin 6	Pdx6	0000302	Response to reactive oxygen species	Sf-PhL; IAV; antioxidant
20	Thioredoxin-like 4B	TXNL4B	0030612	Thioredoxin activity	Antioxidant
Phospholipid Metabolism and Signaling					
8	Calcyclin	S100a6	0048146	Fibroblast proliferation	Growth factor
9	Clara cell protein 10	CC10	0019834	Phospholipase A2 inhibitor	Sf-PhL
13	Oxytocin receptor	OxtR	0004990	Oxytocin receptor activity	
16	Phospholipase A2, secreted	PLA2G12A	0004623	Phospholipase A2 activity	SARS; IAV; Sf-PhL
12	Hydrocephalus-inducing protein	Hydin	0003341	Movement of tracheal cilia	
Molecular Transport/Serum					
5	Albumin	Alb	0006810	Molecular transport in serum	
6	Annexin A5	Anxa5	0050819	Negative regulation of coagulation	Anticoagulant
4	α 2-u-globulin (mj urinary protein 6)	Mup6	0005550	Lipocalin-like pheromone transport	Allergen
7	Apolipoprotein E	ApoE	0017127	Cholesterol, lipid transport in serum	Sf-PhL
17	Plasma retinol binding protein	RBP4	0001972	Plasma retinol and vitamin A carrier	SARS; VA; APR (negative)
18	Retinoic acid binding protein 2	CRABP2	0001972	Retinoic acid (retinol) binding	APR; VA
22	Transthyretin	TTR	0005179	Vitamin A and T4/thyroxine transport	APR; VA

^a Proteins spots from 2D electrophoresis identified by mass spectrometry. ^b Selected Gene Ontology (GO) term. ^c Selected findings in lung diseases: APR, acute phase response; ARDS, acute respiratory distress syndrome; COPD, chronic obstructive pulmonary disease; IAV, influenza A virus infection; IPF, idiopathic pulmonary fibrosis; NF- κ B, nuclear factor κ B induced gene; SARS, severe acute respiratory syndrome caused by SARS-CoV; Sf-PhL, surfactant-phospholipid oxidation/regulation; TB, tuberculosis; VA, vitamin A (retinol/retinoic acid) transport, signaling and metabolism. Refer to text for references and discussion.

3.4. Functional Enrichment Analysis

To gain a more systematic understanding of protein functions induced in response to MHV-68 infection of the lung, we undertook bioinformatics analyses to identify functional enrichment for the 20 of 23 significant or marginally significant proteins identified in MHV-68 BAL. Albumin, a reference serum protein, and protein fragments (Hydin and OxtR) were not included. Among BAL proteins, significantly enriched functional categories included physiological stress ($p = 0.0010$), oxidative stress annotations ($p < 0.0001$), and acute phase response ($p = 0.0028$) (Figure 3). Oxidative stress response proteins included reactive oxygen species (ROS) and detoxifying enzymes (peroxiredoxins, thioredoxins, and superoxide dismutase). Acute phase response (APR) proteins overlapped with other enriched functions, including physiological stress response and signaling ($p = 0.039$). Among signaling proteins, vitamin A (retinoic acid) binding was a significant function ($p = 0.0094$) for three proteins that were also induced in APR: CRABP2, transthyretin (TTR), and plasma retinol binding protein (RBP4). Proteins induced by WT MHV-68 infection were predominantly in the stress response, acute phase, signaling, and oxidative stress categories. Exogenous expression of IL6 in the context of MHV-68 infection primarily induced oxidative stress and APR proteins as well as vitamin A binding protein CRABP2; RBP4 was weakly induced in the context of IL6. Finally, signaling and APR proteins (calcyclin, Clara cell protein 10, and haptoglobin) were found to be less abundant in WT MHV-68 compared to the control (“suppressed by MHV68”, Figure 3) but clearly not oxidative stress proteins.

Functional Enrichment in BAL Proteins	GO:0004601 peroxidase activity	GO:0016209 antioxidant activity	GO:0016491 oxidoreductase activity	IPR012335 thioredoxin fold	MHV68/IL6 induced by MHV68/IL-6	GO:0003824 catalytic activity	GO:0006950 stress response	MHV68 induced by MHV68	GO:0006953 acute phase response	SP_PIR:signal signaling	MHV68 suppressed by MHV68
	Oxidative Stress: $p = 3.7 \times 10^{-5}$; $p_{BH} = 4.7 \times 10^{-5}$					n.s.	$p = 0.0010$		$p_{BH} = 0.0028$	$p = 0.039$	
Calcylin											
Clara cell protein 10											
Haptoglobin											
$\alpha 2$ -u-globulin											
TNF α -induc.pr.8-like2											
Apolipoprotein E											
Annexin A5											
Transthyretin										vit. A*	
$\alpha 1$ -acid glycoprotein B											
IL1 family member 10											
$\alpha 1$ -anti-trypsin/serpinA1											
Phospholipase A2											
Plasma retinol b. pr.										vit. A*	
$\alpha 2$ -macroglobulin											
Retinoic acid binding 2										vit. A*	
Glut-S-transferase mu1											
Thioredoxin-like 4B											
Superoxide dismutase 3											
Peroxiredoxin 6											
Peroxiredoxin 2											

* Vitamin A signaling/transport: $p = 0.0094$

Figure 3. Functional enrichment matrix for identified BAL proteins. Protein functional enrichment for 20 out of 23 BAL proteins identified, clustered by Gene Ontology (GO), InterPro (IPR), and Protein Information Resource (SP_PIR) term annotation, Ingenuity Pathways Analysis (IPA), or regulation by WT MHV-68 (MHV68) and MHV68/IL6 (infex). Dark gray, inclusion in functional term or strong regulation. Light gray, weak induction by MHV-68 or MHV68/IL6. Proteins involved in vitamin A (vit. A*) signaling and transport were enriched within the signaling category with $p = 0.0094$. Significance estimated by p -values (labeled p) for enrichment in annotated functional categories; Benjamini–Hochberg (p_{BH}) false discovery probability values for IPA category analysis. n.s. = not significant.

3.5. Acute Phase and Oxidative Stress Gene Expression in the MHV-68 Infected Lung

To further investigate acute phase and oxidative stress responses in lung tissue, the expression of known host genes involved in these pathways was studied by quantitative real-time (qRT) PCR. Two mice for each condition were infected with WT MHV-68, MHV68/IL6, or mock (DMEM) inoculated, and RNA was extracted from total lung homogenates for qRT-PCR. By seven d.p.i., APR/vitamin A transport genes RBP4 and TTR were upregulated approximately four- and two-fold, respectively, with significantly higher induction by MHV68/IL6 for RBP4 (Figure 4). MHV-68 infection also generally induces oxidative stress genes in the lung by seven d.p.i. (Figure 4), including genes

encoding lung antioxidant proteins Pdx6, EC-SOD, glutathione peroxidase 3 (Gpx3), and thioredoxin 1 (Trx1), as well as inducible nitric oxide synthetase (iNOS), a pro-inflammatory protein that is capable of generating reactive oxygen species (ROS) and reactive nitrogen species (RNS) as a byproduct of the production of NO messenger [74].




Figure 4. MHV-68 infection upregulates stress response genes in the lungs of infected mice. Mice were mock-infected, or infected i.n. with 2×10^5 pfu of WT MHV-68 or MHV68/IL6. Total lung RNA was isolated 7 d.p.i., and qRT-PCR performed with specific primers to murine acute phase, immunomodulatory, oxidative stress response genes, and actin. *p*-values of fold induction estimated from unpaired, 2-tailed *t*-test (sub-table) with $p < 0.01$ (***), $p < 0.05$ (**), $p < 0.1$ (*), or $p > 0.1$ (n.s., not significant). Error bars represent S.E.M. *TIPE2*, *Tnfaip8l2*; *Gpx3*, glutathione peroxidase 3; *iNOS*, inducible nitric oxide synthetase; *SOD3*, (extracellular) superoxide dismutase 3; *Trx1*, thioredoxin 1; *RBP4*, *TTR*, *Pdx6*, as in Table S2.

3.6. Lytic MHV-68 Infection Induces Oxidative Stress in Cultured Fibroblasts

To investigate the autonomous contribution of the MHV-68 lytic phase to oxidative stress in infected cells, we studied the role of the MHV-68 lytic phase in the production of ROS in murine NIH3T3 fibroblasts and human lung epithelioid A549 cells. As a control, we treated uninfected NIH3T3 cells with hydrogen peroxide, and induction of ROS was evident by oxidative green fluorescence of H_2DF_2DA (Figure 5A, upper panel). To examine whether ROS is induced by MHV-68 infection, sub-confluent NIH3T3 or A549 cells were infected with a recombinant MHV-68 virus expressing red fluorescent protein (RFP) from the ORF28 late locus, and then stained with H_2DF_2DA at 20 h.p.i. The majority of infected NIH3T3 or A549 cells (indicated by red fluorescence) exhibited a moderate to bright green H_2DF_2DA oxidative fluorescence, indicative of a high level of ROS (Figure 5A, lower two panels). Roughly 15% of infected NIH3T3 cells exhibited bright H_2DF_2DA oxidative fluorescence, indicative of a high level of ROS, by 20 h.p.i. (Figure 5A). ROS can lead to the generation of peroxides such as H_2O_2 , which are reduced by the multi-subunit catalase enzyme. Indeed, catalase enzyme (Figure 5B) and catalase activity (Figure 5C) were upregulated in NIH3T3 cells infected with WT

MHV-68 (m.o.i. = 1) by 24 h.p.i. In contrast, only basal catalase activity was observed early during MHV-68 infection at two h.p.i. and six h.p.i., analogous to simply adding excess H_2O_2 (Figure 5C). ROS did not accumulate by four h.p.i. even in a high titer infection (m.o.i. = 5), but did by 20 h.p.i. (Figure S3), suggesting that cytotoxicity associated with the late lytic cycle of virus infection is required for the generation of ROS. However, ROS induction itself seems to have little effect on MHV-68 infection; modulating cellular redox potential in infected NIH3T3 cells with sub-lethal doses of the oxidative stress inducer paraquat only weakly enhanced lytic expression of RFP/MHV-68, and quenching ROS with soluble glutathione had little discernable effect (Figure S3).




Figure 5. MHV-68 infection induces reactive oxygen species (ROS) in cultured cells. **(A)** Murine NIH3T3 fibroblasts or human lung A549 cells were infected (m.o.i. = 1) in triplicate with MHV-68 expressing red fluorescent protein (RFP/MHV-68, red channel). Supernatants were removed 20 h.p.i., and the cells were incubated with H_2DF_2DA and imaged by epifluorescence microscopy. Hydrogen peroxide (H_2O_2) was a control for induction of ROS leading to oxidative fluorescence of H_2DF_2DA (green channel). **(B)** NIH3T3 cells infected in triplicate with WT MHV-68 were lysed at the indicated times, proteins separated by SDS-PAGE, and Western blots probed for catalase protein and MHV-68 lytic antigen (ORF65) with specific antibodies and electrochemiluminescent secondary antibody detection. **(C)** Induction of ROS measured by catalase activity assay. NIH3T3 cells in triplicate were untreated, treated with H_2O_2 for 20 h, or infected with WT MHV-68 for the times indicated; cells were lysed and aliquots measured for protein content by Bradford and catalase activity assays according to a standard curve; only for 24 h, $p < 0.05$, two-tailed t -test; error bars represent S.E.M.

3.7. An Oxidative Stress Response Network Induced in Mouse Lungs by MHV-68 Infection

To gain a deeper understanding of the pathways induced in response to MHV-68 infection of the lung and co-expression of IL6, we used Ingenuity Pathways Analysis (IPA) to extract an oxidative stress and inflammatory response network centered on redox proteins identified in this study. While the number of proteins identified in our proteomics study (Table S1) was insufficient for de novo network discovery [60], analog curation using data from the Ingenuity KnowledgeBase and NCBI EntrezGene allowed synthesis of a model depicting regulatory interactions (i.e., activation, inhibition, etc.) among key molecules (Figure 6). A striking feature of the model is the multi-directional interaction between

antioxidant proteins and transcriptional regulatory factors such as COX-2, NF- κ B, and iNOS, all of which have been found to be important to gammaherpesvirus infections [25,52,75].




Figure 6. Oxidative stress network induced in mouse lungs by MHV-68. A sub-network of antioxidant proteins was extracted by IPA and manually curated. MHV-68 lytic infection induces reactive oxygen species (ROS) small molecules (red) that in turn induce oxidative stress response genes. Network model includes proteins induced in infected lungs by MHV-68 (yellow) or by IL6 in the context of MHV-68 infection (orange and orange-border), proteins directly upregulated by MHV-68 lytic infection (pink and pink-border, [52]), and NF- κ B, which has a complex interaction with MHV-68 lytic replication (green, [75]). Antioxidant co-factors (aqua), other redox proteins (gray), activating interactions (arrows), indirect regulation (dashed arrows and bars), and inhibitory interactions (blocking bars) indicate the potential complexity of even a small-scale redox network in vivo.

4. Discussion

We have undertaken a differential proteomics analysis of BAL fluid to gain insight into the pulmonary molecular pathology of respiratory virus infections in mice. As a tractable animal model of gammaherpesvirus infection, the pathogenesis and immune response to MHV-68 in the mouse lung has been a subject of considerable recent inquiry [16,18–21,23,47,64]. In such studies, BAL fluid has been used to analyze immune cell infiltration, cytokine/chemokine profiles, and chemotaxis activity, for example [15,20]. We found molecules in BAL fluid that provide additional insight as virus-induced lung injury is resolved, uncovering molecular details (i.e., host factors and pathways) of the host response to a virus in a quantifiable manner. Proteins induced by nine d.p.i. included oxidative stress response proteins, acute phase proteins, signaling molecules and transporters (Table 1). Functional category analyses indicated that redox, acute phase, and vitamin A proteins were significantly enriched in the subset of BAL proteins we identified (Figure 3), suggesting that these processes are induced by nine d.p.i. in MHV-68 infection of the mouse lung.

4.1. Effects of Co-Expressing IL6

As suggested by experiments in IL6-deficient mice [30], IL6 may play a role in inflammation and the development of lung pathology during MHV-68 infection rather than impacting viral replication. Instead of comparing BAL proteins between WT and IL6-deficient mice, we took a different approach to examine the effects of IL-6 by using an MHV68/IL6 virus that over-expresses this cytokine. Co-expression of IL-6 in MHV-68 infection of the mouse lung showed neither significant difference in replication kinetics nor whole lung viral titers in comparison to wild-type virus. However, MHV68/IL6 induced a subset of BAL proteins, including redox, acute phase, and vitamin A signaling/transport molecules (Figure 2D), as well as type I collagen (Figure 1B). IL6 gene expression is induced by NF- κ B heterodimers, and IL6 in turn signals through an IL6 (CD126) receptor–gp130 co-receptor complex on a subset of B-cells to NF-IL6, a pro-inflammatory transcription factor [76,77]. In the lung, IL6 regulates natural killer (NK) cells responding to MHV-68 infection [30]. KSHV, a human gammaherpesvirus, encodes a viral IL6 homologue that can signal through the gp130 co-receptor found on a range of B-cells, independently of the cellular IL6 receptor [78]. The KSHV lytic transactivator replication and transcription activator (RTA) also activates the human IL6 promoter [79]. In addition, KSHV microRNAs (miRNAs) specifically induce IL6 and IL10 in macrophages [80]. Besides querying the effects of supranormal IL6 levels on infected lung pathophysiology, inclusion of the MHV68/IL6 virus in our BAL proteomics analysis allowed for the development of an analytical IEF/2DE method for differential protein discovery (Figure 2), demonstrating the potential utility of this approach for querying viral mutants.

4.2. Oxidative Stress Response Proteins Are Induced in MHV-68 Infection of the Mouse Lung

In the BAL proteome, host antioxidant and oxidative stress response proteins were upregulated by MHV-68 infection (Table 1), including Pdx6, EC-SOD, and a paralogue of GST (GSTm1). In whole lung tissue, genes encoding iNOS, extracellular glutathione peroxidase (Gpx3), and a thioredoxin (Trx1), were also induced (Figure 4). Co-expression of IL6 in MHV-68 infection further upregulated EC-SOD (Figure 2D), and induced another peroxiredoxin (Pdx2) and a thioredoxin paralogue (TXNL4B). Induction of antioxidant proteins suggests a pathophysiological response in the lungs to oxidative stress. Induction of oxidative stress has been found in experimental virus infections *in vivo*, including RSV in mice [43,81], and influenza virus infections in human epithelial cells, mice [82,83] and macaques [57]. Antioxidant proteins can protect lung tissue from oxidative damage, detoxify oxidized phospholipids, and reduce virus-associated ALI [83–85]. Oxidative stress induced in respiratory virus infections can also have pleiotropic effects on lung gene expression and inflammatory processes such as cytokine and chemokine production [57,82,86].

4.2.1. Sources of Oxidative Stress

We found that MHV-68 infection of cultured NIH3T3 fibroblasts or lung-derived A549 cells induces ROS and catalase activity (Figure 5). Similarly, cultured cells infected with respiratory syncytial virus (RSV), rhesus monkey rhadinovirus (RRV, another gammaherpesvirus), or HSV-1 show increased oxidative stress [43,87–89]. Two genes upregulated by MHV-68, COX-2 [52] and iNOS (Figure 4), are capable of directly generating ROS as reaction byproducts [74,90]. Lytic MHV-68 infection proceeds under conditions of oxidative stress, as we found that treating infected cells with paraquat did not inhibit but rather mildly enhanced RFP/MHV-68 virus infection (Figure S3). *In vivo*, mice treated with NSAID-targeting COX-2 showed no differences in MHV-68 titers than controls ([52]). In contrast, cytotoxic T-lymphocyte (CTL) immune control of MHV-68 is impaired in mice deficient in iNOS, resulting in lethality [25]. While viral infection of type I and II lung epithelial cells likely contributes directly to the induction of oxidative stress, there may be other contributing factors in the alveolar microenvironment, such as degranulation of activated innate immune effector cells (alveolar macrophages, natural killer cells, and neutrophils). For example, the Ncf1/NADPH oxidase complex

in neutrophils also significantly contributes to ROS and oxidation of phospholipids in lungs insulted with H5N1 highly pathogenic avian influenza (HPAI) [70].

4.2.2. Oxidative Damage to Surfactant Phospholipids

Pulmonary surfactant lipids and proteins have roles in antiviral defense and inflammatory and immune responses against respiratory viruses such as influenza A viruses, RSV, and adenovirus [91]. Conversely, oxidative damage to phospholipids is implicated in ALI caused by viruses such as HPAI, SARS-CoV [70], and RSV [81]. Oxidized phospholipids that accumulate in HPAI and SARS-CoV infections also likely contribute to ALI and hypercytokinemia (“cytokine storm”) by signaling through toll-like receptor 4 (TLR4) and TRIF/TICAM1 in macrophages, activating NF- κ B and inducing IL6 [70]. We found PLA2G12A, a secreted phospholipase A2 enzyme, highly upregulated in BAL from MHV-68 infected mice at nine d.p.i. (Table 1 and Figure 2D). Phospholipase A2 enzymes are involved in the degradation of damaged (oxidized) surfactant phospholipids including dipalmitoyl phosphatidylcholine (DPPC), a process often upregulated in lung injury. Phospholipase A2 is inhibited by abundant surfactant proteins including surfactant protein A (SP-A; [92]), and Clara cell protein 10 (CC10), which was downregulated in BAL from MHV-68 infection (Figure 2D). Another protein induced in BAL, Pdx6, may reduce oxidized phospholipids, including DPPC, that have been modified by ROS, allowing lipid recycling in type II epithelial cells or macrophages in the lungs [93–95]. Accordingly, surfactant protein expression is altered in chronic MHV-68 infection of interferon gamma receptor (IFNGR)-null mice that display a pathology reminiscent of IPF [15]. These findings suggest a role for lung surfactant lipids and lipid-associated proteins in the pathogenesis of MHV-68 in the lungs.

4.2.3. Comparison to other Respiratory Diseases and Role of Nrf2

In contrast to MHV-68 infection, expression of antioxidant (oxidative stress response) proteins SOD1, GPx1, Pdx6, GSTmu1, and catalase were suppressed during RSV infection in the lungs of mice and human patients [43]. The antioxidant transcription factor Nrf2 was also suppressed in RSV infection, while Pdx2 was induced like in MHV-68 infection. The importance of the Nrf2-mediated response was illustrated in knockout mice, whereby Nrf2 protected lung cells from bronchopulmonary injury by RSV and influenza A virus [81,82]. Interestingly, a close association between oxidative stress and pro-fibrotic inflammation in the lung, marked by elevated Nrf2 expression, is well-established in human patients with IPF and/or interstitial pneumonia [96,97]. Human Pdx2 particularly has also been found upregulated in UIP/IPF lung tissue, in particular in alveolar macrophages [98]. Thus, the role of Nrf2 in the induction of antioxidant defenses and pro-fibrotic pathophysiology of MHV-68 is in need of further investigation.

4.3. Modeling a Complex Relationship

A network of molecules intersects with these antioxidant proteins, including NF- κ B, IL6, COX-2, iNOS, Nrf2, and small molecules, suggesting multiple points at which MHV-68 infection might generate an oxidative stress in the lungs (Figure 6). For example, while it is suspected that NF- κ B can be activated by oxidative stress in viral infections [81,82], the relationship between NF- κ B signaling and gammaherpesvirus pathogenesis is complex and poorly understood. It has been reported that NF- κ B is activated by MHV-68 lytic replication [63], while paradoxically, NF- κ B activation can also inhibit the initiation of MHV-68 lytic replication [75]. Regulation of NF- κ B is an enriched function among cellular proteins interacting with MHV-68 proteins [99], and the lytic protein ORF73 promotes ubiquitination and degradation of p65/RelA [100]. Likewise, inhibition of NF- κ B leads to upregulation of ROS and reactivation of latent KSHV by activating expression of the lytic transactivator protein, RTA [101]. Moreover, experimental inhibition of NF- κ B blocks chemokine responses and development of pulmonary fibrosis in the lung in MHV-68 infection [63]. Functional genomics studies may provide additional molecular insight into virus–host interactions controlling MHV-68 infection and induction of oxidative stress [99].

4.3.1. Acute Phase Response

Appearance of acute phase proteins in the serum is a hallmark of systemic inflammation resulting from infections, including bacterial sepsis, pneumonia, and human immunodeficiency virus (HIV-1) [102–105]. The release of acute phase proteins from liver hepatocytes or other tissues is dependent on IL6 and other cytokines [106,107]. The finding of acute phase proteins in BAL from MHV-68 infected mice indicate a systemic response to intranasal MHV-68 infection, or leakage of serum proteins into the pleural interstitial and alveolar lumen, consistent with previous findings of UIP pathology in MHV-68 infection [16]. We found acute phase-related proteins in BAL at nine d.p.i., including α 1-antitrypsin (A1AT6), α 2-macroglobulin (A2MP), α 1-acid glycoprotein 1B (A1AG1/AGP), haptoglobin, and vitamin A transport molecules CRABP2, TTR, and RBP4 (Table 1 and Figure 3). AGP is immunomodulatory, induced in experimental pulmonary tuberculosis [108] and influenza [72] in mice. A1AT6 is a protease inhibitor induced by MHV-68, while the endopeptidase haptoglobin is suppressed (Figure 2D); along with type I collagen accumulation (Figure 1B), an anti-proteolytic lung tissue remodeling environment is apparent. IL6 has also been suggested to enhance the production of acute phase response proteins in virus infections [106]. Indeed, the protease inhibitor A2MP is induced in MHV68/IL6 infection (Figure 2D), consistent with higher type I collagen deposition. Finally, vitamin A (retinoic acid, RA) is a signaling molecule carried in the serum as all-trans retinol by an RBP4 and TTR dimer complex [109]. Vitamin A inhibits HSV-1 [110] and KSHV [111] replication in cell culture. Vitamin A can activate the immune response to infection in the respiratory tract, for example, by enhancing Th2 responses and IgA secretion in influenza virus infection of mice [112]. In the lungs, vitamin A counter-acts IL6 and protects against bleomycin-induced fibrotic lung injury [113,114]. The immunoregulatory function of vitamin A is not understood in MHV-68 infection.

4.3.2. Other Immunomodulatory Proteins in BAL Fluid

One gene encoding an immune modulator, Tnfrsf8l2, was induced in BAL by MHV-68 infection by nine d.p.i. (Table S2). While LC/MS-MS peptide data identification of this protein was of marginal significance ($p < 0.1$), the gene encoding Tnfrsf8l2 was also weakly upregulated in lung tissue by seven d.p.i. (Figure 4). TNF α -interacting protein 8 members, including Tnfrsf8l2 (TIPE2), form a conserved gene family in humans and mice (Figure S4) involved in immune homeostasis. TIPE2 downregulates inflammatory responses mediated by toll-like receptors (TLR), T-cell receptors (TCR), and NF κ B signaling, which in turn promotes Fas-mediated apoptosis in lymphoid cells [115]. Except for Tnfrsf8l2 and a weak match to annexin A5, we did not find other cell death regulators in BAL at nine d.p.i. Cell death in MHV-68 infection has been found to be mediated by CD8+ CTL in the lung [23], while a viral Bcl2 encoded in the MHV-68 genome blocks internal cell death mechanisms such as autophagy in infected cells [116].

4.4. Limitations of This Study

Our BAL processing protocol enriched for differentially-expressed proteins remaining after the reduction of abundant high-MW macromolecules, including albumin, immunoglobulins, and serum proteins (Figure 1C). While this approach allowed us to resolve less-abundant proteins, it likely missed potentially interesting proteins associated with the removed macromolecules. We also did not detect a high diversity of cytokines in post-processed BAL, possibly because of their relatively low abundances, interactions with antibodies or albumin, or failure to isolate highly basic proteins in the purification schema. Variant protocols enriching different BAL fractions, or using different BAL solvents, and new mass spectrometry technologies are in development.

5. Conclusions

Experimental MHV-68 Infection of the Mouse as a Model for Lung Diseases

The induction of and responses to oxidative stress appear to be a common theme in the pathophysiology of interstitial lung diseases, including infections such as MHV-68 (this study and [15]), SARS-coronavirus [69], influenza A virus [70,82], RSV [43], and in chronic diseases such as COPD [117] and IPF [96]. Interestingly, a number of the gene products we identified as differentially regulated by MHV-68 infection in BAL were also found to be associated with these diseases (Table 1). Differential proteomics analysis of mouse BAL fluid opens a new window into understanding the pathogenesis of MHV-68 and other respiratory viruses, and MHV-68 models of chronic lung diseases such as IPF [15]. The proteins identified herein are potential biomarkers for pulmonary virus infections generating high levels of oxidative stress and aggravating other pathophysiological responses, such as acute phase (Figure 3) and surfactant lipid damage. We propose continuing application of differential BAL proteomics in conjunction with whole-lung genomics and proteomics analyses [57,118] to integrate a systems understanding of immune responses and virus-induced pathological changes to the pleura.

Supplementary Materials: The following are available online at <http://www.mdpi.com/1999-4915/10/12/670/s1>, Table S1: Proteomics identification of proteins in murine BAL fluid from MHV-68 infection, Table S2. RT-PCR primers used in this study, Figure S1. Analysis of viral and cellular components in BAL fluid. Figure S2. One of the LC/MS-MS spectra identifying mouse Pdx6. Figure S3. Dynamics of ROS generation in MHV-68 infection of cultured cells. Figure S4. Tnfaip8l2 is a member of a conserved gene family in human and mouse.

Author Contributions: E.B., T.-T.W. and R.S. conceived and designed the experiments; E.B. and J.P.W. performed the experiments; E.B., P.P., J.P.W., T.-T.W. and R.S. analyzed the data; E.B. wrote the paper.

Funding: This work was supported by a Genomics Seed Grant from the Jonsson Comprehensive Cancer Center at UCLA and NIH (to R.S.); UCSD/UCLA NIDDK Diabetes Research Center P30 DK063491 (to J.P.W.); and a pilot award from NIGMS Alaska INBRE P20GM103395 (to E.B.).

Acknowledgments: We would like to thank Sara Bassilian, Pete Psoudas, James Kerwin, and Kym Faull of the Proteomics Shared Resource at UCLA; Leming Tong, Zhou Zhou, Seungmin Hwang, Xudong Li and Neil Bortz for technical assistance; and Jason Burkhead (UAA) for helpful discussions.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Belser, J.A.; Maines, T.R.; Tumpey, T.M.; Katz, J.M. Influenza A virus transmission: Contributing factors and clinical implications. *Expert Rev. Mol. Med.* **2010**, *12*, e39. [CrossRef] [PubMed]
2. Do Carmo Debur, M.; Raboni, S.M.; Flizikowski, F.B.; Chong, D.C.; Persicote, A.P.; Nogueira, M.B.; Rosele, L.V.; de Almeida, S.M.; de Noronha, L. Immunohistochemical assessment of respiratory viruses in necropsy samples from lethal non-pandemic seasonal respiratory infections. *J. Clin. Pathol.* **2010**, *63*, 930–934. [CrossRef] [PubMed]
3. Gao, R.; Dong, L.; Dong, J.; Wen, L.; Zhang, Y.; Yu, H.; Feng, Z.; Chen, M.; Tan, Y.; Mo, Z.; et al. A systematic molecular pathology study of a laboratory confirmed H5N1 human case. *PLoS ONE* **2010**, *5*, e13315. [CrossRef] [PubMed]
4. Kaye, M.; Skidmore, S.; Osman, H.; Weinbren, M.; Warren, R. Surveillance of respiratory virus infections in adult hospital admissions using rapid methods. *Epidemiol. Infect.* **2006**, *134*, 792–798. [CrossRef] [PubMed]
5. Ksiazek, T.G.; Erdman, D.; Goldsmith, C.S.; Zaki, S.R.; Peret, T.; Emery, S.; Tong, S.; Urbani, C.; Comer, J.A.; Lim, W.; et al. A novel coronavirus associated with severe acute respiratory syndrome. *N. Engl. J. Med.* **2003**, *348*, 1953–1966. [CrossRef] [PubMed]
6. Papenburg, J.; Boivin, G. The distinguishing features of human metapneumovirus and respiratory syncytial virus. *Rev. Med. Virol.* **2010**, *20*, 245–260. [CrossRef] [PubMed]
7. Quan, P.L.; Palacios, G.; Jabado, O.J.; Conlan, S.; Hirschberg, D.L.; Pozo, F.; Jack, P.J.; Cisterna, D.; Renwick, N.; Hui, J.; et al. Detection of respiratory viruses and subtype identification of influenza A viruses by GreeneChipResp oligonucleotide microarray. *J. Clin. Microbiol.* **2007**, *45*, 2359–2364. [CrossRef] [PubMed]

8. Estenssoro, E.; Rios, F.G.; Apezteguia, C.; Reina, R.; Neira, J.; Ceraso, D.H.; Orlandi, C.; Valentini, R.; Tiribelli, N.; Brizuela, M.; et al. Pandemic 2009 influenza A in Argentina: A study of 337 patients on mechanical ventilation. *Am. J. Respir. Crit. Care Med.* **2010**, *182*, 41–48. [[CrossRef](#)] [[PubMed](#)]
9. Koegelenberg, C.F.; Irusen, E.M.; Cooper, R.; Diacon, A.H.; Taljaard, J.J.; Mowlana, A.; von Groote-Bidlingmaier, F.; Bolliger, C.T. High mortality from respiratory failure secondary to swine-origin influenza A (H1N1) in South Africa. *QJM* **2010**, *103*, 319–325. [[CrossRef](#)] [[PubMed](#)]
10. Mohan, A.; Chandra, S.; Agarwal, D.; Guleria, R.; Broor, S.; Gaur, B.; Pandey, R.M. Prevalence of viral infection detected by PCR and RT-PCR in patients with acute exacerbation of COPD: A systematic review. *Respirology* **2010**, *15*, 536–542. [[CrossRef](#)] [[PubMed](#)]
11. Satterwhite, L.; Mehta, A.; Martin, G.S. Novel findings from the second wave of adult pH1N1 in the United States. *Crit. Care Med.* **2010**, *38*, 2059–2061. [[CrossRef](#)] [[PubMed](#)]
12. Bhoopat, L.; Rangakulnuwat, S.; Okonogi, R.; Wannasai, K.; Bhoopat, T. Cell reservoirs of the Epstein-Barr virus in biopsy-proven lymphocytic interstitial pneumonitis in HIV-1 subtype E infected children: Identification by combined in situ hybridization and immunohistochemistry. *Appl. Immunohistochem. Mol. Morphol.* **2010**, *18*, 212–218. [[CrossRef](#)] [[PubMed](#)]
13. Barbera, J.A.; Hayashi, S.; Hegele, R.G.; Hogg, J.C. Detection of Epstein-Barr virus in lymphocytic interstitial pneumonia by in situ hybridization. *Am. Rev. Respir. Dis.* **1992**, *145*, 940–946. [[CrossRef](#)] [[PubMed](#)]
14. Muller, A.; Franzen, C.; Klusmann, P.; Wagner, M.; Diehl, V.; Fatkenheuer, G.; Salzberger, B.; Ablashi, D.V.; Krueger, G.R. Human herpesvirus type 8 in HIV-infected patients with interstitial pneumonitis. *J. Infect.* **2000**, *40*, 242–247. [[CrossRef](#)] [[PubMed](#)]
15. Mora, A.L.; Torres-Gonzalez, E.; Rojas, M.; Xu, J.; Ritzenthaler, J.; Speck, S.H.; Roman, J.; Brigham, K.; Stecenko, A. Control of virus reactivation arrests pulmonary herpesvirus-induced fibrosis in IFN-gamma receptor-deficient mice. *Am. J. Respir. Crit. Care Med.* **2007**, *175*, 1139–1150. [[CrossRef](#)] [[PubMed](#)]
16. Hughes, D.J.; Kipar, A.; Sample, J.T.; Stewart, J.P. Pathogenesis of a model gammaherpesvirus in a natural host. *J. Virol.* **2010**, *84*, 3949–3961. [[CrossRef](#)] [[PubMed](#)]
17. Weslow-Schmidt, J.L.; Jewell, N.A.; Mertz, S.E.; Simas, J.P.; Durbin, J.E.; Flano, E. Type I interferon inhibition and dendritic cell activation during gammaherpesvirus respiratory infection. *J. Virol.* **2007**, *81*, 9778–9789. [[CrossRef](#)] [[PubMed](#)]
18. Lee, K.S.; Cool, C.D.; van Dyk, L.F. Murine gammaherpesvirus 68 infection of gamma interferon-deficient mice on a BALB/c background results in acute lethal pneumonia that is dependent on specific viral genes. *J. Virol.* **2009**, *83*, 11397–11401. [[CrossRef](#)] [[PubMed](#)]
19. Sarawar, S.R.; Cardin, R.D.; Brooks, J.W.; Mehrpooya, M.; Hamilton-Easton, A.M.; Mo, X.Y.; Doherty, P.C. Gamma interferon is not essential for recovery from acute infection with murine gammaherpesvirus 68. *J. Virol.* **1997**, *71*, 3916–3921. [[PubMed](#)]
20. Sarawar, S.R.; Lee, B.J.; Anderson, M.; Teng, Y.C.; Zuberi, R.; Von Gesjen, S. Chemokine induction and leukocyte trafficking to the lungs during murine gammaherpesvirus 68 (MHV-68) infection. *Virology* **2002**, *293*, 54–62. [[CrossRef](#)] [[PubMed](#)]
21. Sarawar, S.R.; Cardin, R.D.; Brooks, J.W.; Mehrpooya, M.; Tripp, R.A.; Doherty, P.C. Cytokine production in the immune response to murine gammaherpesvirus 68. *J. Virol.* **1996**, *70*, 3264–3268. [[PubMed](#)]
22. Dutia, B.M.; Allen, D.J.; Dyson, H.; Nash, A.A. Type I interferons and IRF-1 play a critical role in the control of a gammaherpesvirus infection. *Virology* **1999**, *261*, 173–179. [[CrossRef](#)] [[PubMed](#)]
23. Ehtisham, S.; Sunil-Chandra, N.P.; Nash, A.A. Pathogenesis of murine gammaherpesvirus infection in mice deficient in CD4 and CD8 T cells. *J. Virol.* **1993**, *67*, 5247–5252. [[PubMed](#)]
24. Fuse, S.; Obar, J.J.; Bellfy, S.; Leung, E.K.; Zhang, W.; Usherwood, E.J. CD80 and CD86 control antiviral CD8+ T-cell function and immune surveillance of murine gammaherpesvirus 68. *J. Virol.* **2006**, *80*, 9159–9170. [[CrossRef](#)] [[PubMed](#)]
25. Kulkarni, A.B.; Holmes, K.L.; Fredrickson, T.N.; Hartley, J.W.; Morse, H.C., 3rd. Characteristics of a murine gammaherpesvirus infection immunocompromised mice. *In Vivo* **1997**, *11*, 281–291. [[PubMed](#)]
26. Dias, P.; Shea, A.L.; Inglis, C.; Giannoni, F.; Lee, L.N.; Sarawar, S.R. Primary clearance of murine gammaherpesvirus 68 by PKC θ -/- CD8 T cells is compromised in the absence of help from CD4 T cells. *J. Virol.* **2008**, *82*, 11970–11975. [[CrossRef](#)] [[PubMed](#)]

27. McMillan, T.R.; Moore, B.B.; Weinberg, J.B.; Vannella, K.M.; Fields, W.B.; Christensen, P.J.; van Dyk, L.F.; Toews, G.B. Exacerbation of established pulmonary fibrosis in a murine model by gammaherpesvirus. *Am. J. Respir. Crit. Care Med.* **2008**, *177*, 771–780. [[CrossRef](#)] [[PubMed](#)]
28. Lin, W.C.; Lin, C.F.; Chen, C.L.; Chen, C.W.; Lin, Y.S. Prediction of outcome in patients with acute respiratory distress syndrome by bronchoalveolar lavage inflammatory mediators. *Exp. Biol. Med.* **2010**, *235*, 57–65. [[CrossRef](#)] [[PubMed](#)]
29. Xie, X.H.; Law, H.K.; Wang, L.J.; Li, X.; Yang, X.Q.; Liu, E.M. Lipopolysaccharide induces IL-6 production in respiratory syncytial virus-infected airway epithelial cells through the toll-like receptor 4 signaling pathway. *Pediatr. Res.* **2009**, *65*, 156–162. [[CrossRef](#)] [[PubMed](#)]
30. Sarawar, S.R.; Brooks, J.W.; Cardin, R.D.; Mehrpooya, M.; Doherty, P.C. Pathogenesis of murine gammaherpesvirus-68 infection in interleukin-6-deficient mice. *Virology* **1998**, *249*, 359–366. [[CrossRef](#)] [[PubMed](#)]
31. Chatterjee, M.; Osborne, J.; Bestetti, G.; Chang, Y.; Moore, P.S. Viral IL-6-induced cell proliferation and immune evasion of interferon activity. *Science* **2002**, *298*, 1432–1435. [[CrossRef](#)] [[PubMed](#)]
32. Hu, F.; Nicholas, J. Signal transduction by human herpesvirus 8 viral interleukin-6 (vIL-6) is modulated by the non-signaling gp80 subunit of the IL-6 receptor complex and is distinct from signaling induced by human IL-6. *J. Virol.* **2006**, *80*, 10874–10878. [[CrossRef](#)] [[PubMed](#)]
33. Gharib, S.A.; Nguyen, E.; Altemeier, W.A.; Shaffer, S.A.; Doneanu, C.E.; Goodlett, D.R.; Schnapp, L.M. Of mice and men: Comparative proteomics of bronchoalveolar fluid. *Eur. Respir. J.* **2009**, *35*, 1388–1395. [[CrossRef](#)] [[PubMed](#)]
34. Wattiez, R.; Falmagne, P. Proteomics of bronchoalveolar lavage fluid. *J. Chromatogr. B Anal. Technol. Biomed. Life Sci.* **2005**, *815*, 169–178. [[CrossRef](#)] [[PubMed](#)]
35. De Torre, C.; Ying, S.X.; Munson, P.J.; Meduri, G.U.; Suffredini, A.F. Proteomic analysis of inflammatory biomarkers in bronchoalveolar lavage. *Proteomics* **2006**, *6*, 3949–3957. [[CrossRef](#)] [[PubMed](#)]
36. Schnapp, L.M.; Donohoe, S.; Chen, J.; Sunde, D.A.; Kelly, P.M.; Ruzinski, J.; Martin, T.; Goodlett, D.R. Mining the acute respiratory distress syndrome proteome: Identification of the insulin-like growth factor (IGF)/IGF-binding protein-3 pathway in acute lung injury. *Am. J. Pathol.* **2006**, *169*, 86–95. [[CrossRef](#)] [[PubMed](#)]
37. Rottoli, P.; Magi, B.; Perari, M.G.; Liberatori, S.; Nikiforakis, N.; Bargagli, E.; Cianti, R.; Bini, L.; Pallini, V. Cytokine profile and proteome analysis in bronchoalveolar lavage of patients with sarcoidosis, pulmonary fibrosis associated with systemic sclerosis and idiopathic pulmonary fibrosis. *Proteomics* **2005**, *5*, 1423–1430. [[CrossRef](#)] [[PubMed](#)]
38. Plymoth, A.; Lofdahl, C.G.; Ekberg-Jansson, A.; Dahlback, M.; Broberg, P.; Foster, M.; Fehniger, T.E.; Marko-Varga, G. Protein expression patterns associated with progression of chronic obstructive pulmonary disease in bronchoalveolar lavage of smokers. *Clin. Chem.* **2007**, *53*, 636–644. [[CrossRef](#)] [[PubMed](#)]
39. Haque, R.; Umstead, T.M.; Freeman, W.M.; Floros, J.; Phelps, D.S. The impact of surfactant protein-A on ozone-induced changes in the mouse bronchoalveolar lavage proteome. *Proteome Sci.* **2009**, *7*, 12. [[CrossRef](#)] [[PubMed](#)]
40. Zhang, L.; Wang, M.; Kang, X.; Boontheung, P.; Li, N.; Nel, A.E.; Loo, J.A. Oxidative stress and asthma: Proteome analysis of chitinase-like proteins and FIZZ1 in lung tissue and bronchoalveolar lavage fluid. *J. Proteome Res.* **2009**, *8*, 1631–1638. [[CrossRef](#)] [[PubMed](#)]
41. Carey, M.A.; Bradbury, J.A.; Reboloso, Y.D.; Graves, J.P.; Zeldin, D.C.; Germolec, D.R. Pharmacologic inhibition of COX-1 and COX-2 in influenza A viral infection in mice. *PLoS ONE* **2010**, *5*, e11610. [[CrossRef](#)] [[PubMed](#)]
42. Brown, J.N.; Estep, R.D.; Lopez-Ferrer, D.; Brewer, H.M.; Clauss, T.R.; Manes, N.P.; O'Connor, M.; Li, H.; Adkins, J.N.; Wong, S.W.; et al. Characterization of macaque pulmonary fluid proteome during monkeypox infection: Dynamics of host response. *Mol. Cell. Proteom.* **2010**, *9*, 2760–2771. [[CrossRef](#)] [[PubMed](#)]
43. Hosakote, Y.M.; Liu, T.; Castro, S.M.; Garofalo, R.P.; Casola, A. Respiratory syncytial virus induces oxidative stress by modulating antioxidant enzymes. *Am. J. Respir. Cell Mol. Biol.* **2009**, *41*, 348–357. [[CrossRef](#)] [[PubMed](#)]
44. Ventura, C.L.; Higdon, R.; Hohmann, L.; Martin, D.; Kolker, E.; Liggitt, H.D.; Skerrett, S.J.; Rubens, C.E. *Staphylococcus aureus* elicits marked alterations in the airway proteome during early pneumonia. *Infect. Immun.* **2008**, *76*, 5862–5872. [[CrossRef](#)] [[PubMed](#)]

45. Ventura, C.L.; Higdon, R.; Kolker, E.; Skerrett, S.J.; Rubens, C.E. Host airway proteins interact with *Staphylococcus aureus* during early pneumonia. *Infect. Immun.* **2008**, *76*, 888–898. [[CrossRef](#)] [[PubMed](#)]
46. Ali, M.; Umstead, T.M.; Haque, R.; Mikerov, A.N.; Freeman, W.M.; Floros, J.; Phelps, D.S. Differences in the BAL proteome after *Klebsiella pneumoniae* infection in wild type and SP-A-/- mice. *Proteome Sci.* **2010**, *8*, 34. [[CrossRef](#)] [[PubMed](#)]
47. Stoolman, J.S.; Vannella, K.M.; Coomes, S.M.; Wilke, C.A.; Sisson, T.H.; Toews, G.B.; Moore, B.B. Latent Infection by Gammaherpesvirus Stimulates Pro-fibrotic Mediator Release from Multiple Cell Types. *Am. J. Physiol. Lung Cell. Mol. Physiol.* **2010**, *300*, L274–L285. [[CrossRef](#)]
48. Isaacs, C.E.; Xu, W.; Pullarkat, R.K.; Kascak, R. Retinoic acid reduces the yield of herpes simplex virus in Vero cells and alters the N-glycosylation of viral envelope proteins. *Antiviral Res.* **2000**, *47*, 29–40. [[CrossRef](#)]
49. Caselli, E.; Galvan, M.; Santoni, F.; Alvarez, S.; de Lera, A.R.; Ivanova, D.; Gronemeyer, H.; Caruso, A.; Guidoboni, M.; Cassai, E.; et al. Retinoic acid analogues inhibit human herpesvirus 8 replication. *Antivir. Ther.* **2008**, *13*, 199–209. [[PubMed](#)]
50. Cui, D.; Moldoveanu, Z.; Stephensen, C.B. High-level dietary vitamin A enhances T-helper type 2 cytokine production and secretory immunoglobulin A response to influenza A virus infection in BALB/c mice. *J. Nutr.* **2000**, *130*, 1132–1139. [[CrossRef](#)] [[PubMed](#)]
51. Tabata, C.; Kadokawa, Y.; Tabata, R.; Takahashi, M.; Okoshi, K.; Sakai, Y.; Mishima, M.; Kubo, H. All-trans-retinoic acid prevents radiation- or bleomycin-induced pulmonary fibrosis. *Am. J. Respir. Crit. Care Med.* **2006**, *174*, 1352–1360. [[CrossRef](#)] [[PubMed](#)]
52. Ebrahimi, B.; Dutia, B.M.; Brownstein, D.G.; Nash, A.A. Murine gammaherpesvirus-68 infection causes multi-organ fibrosis and alters leukocyte trafficking in interferon-gamma receptor knockout mice. *Am. J. Pathol.* **2001**, *158*, 2117–2125. [[CrossRef](#)]
53. Symensma, T.L.; Martinez-Guzman, D.; Jia, Q.; Bortz, E.; Wu, T.T.; Rudra-Ganguly, N.; Cole, S.; Herschman, H.; Sun, R. COX-2 induction during murine gammaherpesvirus 68 infection leads to enhancement of viral gene expression. *J. Virol.* **2003**, *77*, 12753–12763. [[CrossRef](#)] [[PubMed](#)]
54. Tabata, C.; Kubo, H.; Tabata, R.; Wada, M.; Sakuma, K.; Ichikawa, M.; Fujita, S.; Mio, T.; Mishima, M. All-trans retinoic acid modulates radiation-induced proliferation of lung fibroblasts via IL-6/IL-6R system. *Am. J. Physiol. Lung Cell. Mol. Physiol.* **2006**, *290*, L597–L606. [[CrossRef](#)] [[PubMed](#)]
55. Sun, H.; Gong, S.; Carmody, R.J.; Hilliard, A.; Li, L.; Sun, J.; Kong, L.; Xu, L.; Hilliard, B.; Hu, S.; et al. TIPE2, a negative regulator of innate and adaptive immunity that maintains immune homeostasis. *Cell* **2008**, *133*, 415–426. [[CrossRef](#)] [[PubMed](#)]
56. Xiaofei, E.; Hwang, S.; Oh, S.; Lee, J.S.; Jeong, J.H.; Gwack, Y.; Kowalik, T.F.; Sun, R.; Jung, J.U.; Liang, C. Viral Bcl-2-mediated evasion of autophagy aids chronic infection of gammaherpesvirus 68. *PLoS Pathog.* **2009**, *5*, e1000609.
57. Sun, J.; Druhan, L.J.; Zweier, J.L. Reactive oxygen and nitrogen species regulate inducible nitric oxide synthase function shifting the balance of nitric oxide and superoxide production. *Arch. Biochem. Biophys.* **2010**, *494*, 130–137. [[CrossRef](#)] [[PubMed](#)]
58. Rahman, I. Oxidative stress in pathogenesis of chronic obstructive pulmonary disease: Cellular and molecular mechanisms. *Cell Biochem. Biophys.* **2005**, *43*, 167–188. [[CrossRef](#)]
59. Maglott, D.; Ostell, J.; Pruitt, K.D.; Tatusova, T. Entrez Gene: Gene-centered information at NCBI. *Nucleic Acids Res.* **2010**, *39*, D52–D57. [[CrossRef](#)] [[PubMed](#)]
60. Lok, S.S.; Haider, Y.; Howell, D.; Stewart, J.P.; Hasleton, P.S.; Egan, J.J. Murine gammaherpes virus as a cofactor in the development of pulmonary fibrosis in bleomycin resistant mice. *Eur. Respir. J.* **2002**, *20*, 1228–1232. [[CrossRef](#)] [[PubMed](#)]
61. Brown, J.N.; Palermo, R.E.; Baskin, C.R.; Gritsenko, M.; Sabourin, P.J.; Long, J.P.; Sabourin, C.L.; Bielefeldt-Ohmann, H.; Garcia-Sastre, A.; Albrecht, R.; et al. Macaque proteome response to highly pathogenic avian influenza and 1918 reassortant influenza virus infections. *J. Virol.* **2010**, *84*, 12058–12068. [[CrossRef](#)] [[PubMed](#)]
62. Bortz, E.; Wang, L.; Jia, Q.; Wu, T.T.; Whitelegge, J.P.; Deng, H.; Zhou, Z.H.; Sun, R. Murine gammaherpesvirus 68 ORF52 encodes a tegument protein required for virion morphogenesis in the cytoplasm. *J. Virol.* **2007**, *81*, 10137–10150. [[CrossRef](#)] [[PubMed](#)]

63. Hwang, S.; Wu, T.T.; Tong, L.M.; Kim, K.S.; Martinez-Guzman, D.; Colantonio, A.D.; Uittenbogaart, C.H.; Sun, R. Persistent gammaherpesvirus replication and dynamic interaction with the host in vivo. *J. Virol.* **2008**, *82*, 12498–12509. [[CrossRef](#)] [[PubMed](#)]
64. Wu, T.T.; Liao, H.I.; Tong, L.; Leang, R.S.; Smith, G.; Sun, R. Construction and characterization of an infectious murine gammaherpesvirus-68 bacterial artificial chromosome. *J. Biomed. Biotechnol.* **2011**, *2011*, 926258. [[CrossRef](#)] [[PubMed](#)]
65. May, J.S.; Coleman, H.M.; Boname, J.M.; Stevenson, P.G. Murine gammaherpesvirus-68 ORF28 encodes a non-essential virion glycoprotein. *J. Gen. Virol.* **2005**, *86*, 919–928. [[CrossRef](#)] [[PubMed](#)]
66. Jia, Q.; Chernishof, V.; Bortz, E.; McHardy, I.; Wu, T.T.; Liao, H.I.; Sun, R. Murine gammaherpesvirus 68 open reading frame 45 plays an essential role during the immediate-early phase of viral replication. *J. Virol.* **2005**, *79*, 5129–5141. [[CrossRef](#)] [[PubMed](#)]
67. Bortz, E.; Whitelegge, J.P.; Jia, Q.; Zhou, Z.H.; Stewart, J.P.; Wu, T.T.; Sun, R. Identification of proteins associated with murine gammaherpesvirus 68 virions. *J. Virol.* **2003**, *77*, 13425–13432. [[CrossRef](#)] [[PubMed](#)]
68. Gomez, S.M.; Bil, K.Y.; Aguilera, R.; Nishio, J.N.; Faull, K.F.; Whitelegge, J.P. Transit peptide cleavage sites of integral thylakoid membrane proteins. *Mol. Cell. Proteom.* **2003**, *2*, 1068–1085. [[CrossRef](#)] [[PubMed](#)]
69. Shoemaker, L.D.; Orozco, N.M.; Geschwind, D.H.; Whitelegge, J.P.; Faull, K.F.; Kornblum, H.I. Identification of differentially expressed proteins in murine embryonic and postnatal cortical neural progenitors. *PLoS ONE* **2010**, *5*, e9121. [[CrossRef](#)] [[PubMed](#)]
70. Palagi, P.M.; Lisacek, F.; Appel, R.D. Database interrogation algorithms for identification of proteins in proteomic separations. *Methods Mol. Biol.* **2009**, *519*, 515–531. [[PubMed](#)]
71. Baskin, C.R.; Garcia-Sastre, A.; Tumpey, T.M.; Bielefeldt-Ohmann, H.; Carter, V.S.; Nistal-Villan, E.; Katze, M.G. Integration of clinical data, pathology, and cDNA microarrays in influenza virus-infected pigtailed macaques (*Macaca nemestrina*). *J. Virol.* **2004**, *78*, 10420–10432. [[CrossRef](#)] [[PubMed](#)]
72. Benjamini, Y.; Drai, D.; Elmer, G.; Kafkafi, N.; Golani, I. Controlling the false discovery rate in behavior genetics research. *Behav. Brain Res.* **2001**, *125*, 279–284. [[CrossRef](#)]
73. Dennis, G., Jr.; Sherman, B.T.; Hosack, D.A.; Yang, J.; Gao, W.; Lane, H.C.; Lempicki, R.A. DAVID: Database for Annotation, Visualization, and Integrated Discovery. *Genome Biol.* **2003**, *4*, P3. [[CrossRef](#)] [[PubMed](#)]
74. Katoh, K.; Kuma, K.; Toh, H.; Miyata, T. MAFFT version 5: Improvement in accuracy of multiple sequence alignment. *Nucleic Acids Res.* **2005**, *33*, 511–518. [[CrossRef](#)] [[PubMed](#)]
75. Krug, L.T.; Torres-Gonzalez, E.; Qin, Q.; Sorescu, D.; Rojas, M.; Stecenko, A.; Speck, S.H.; Mora, A.L. Inhibition of NF-kappaB signaling reduces virus load and gammaherpesvirus-induced pulmonary fibrosis. *Am. J. Pathol.* **2010**, *177*, 608–621. [[CrossRef](#)] [[PubMed](#)]
76. Veenstra, T.D.; Conrads, T.P.; Hood, B.L.; Avellino, A.M.; Ellenbogen, R.G.; Morrison, R.S. Biomarkers: Mining the biofluid proteome. *Mol. Cell. Proteom.* **2005**, *4*, 409–418. [[CrossRef](#)] [[PubMed](#)]
77. Gharib, S.A.; Vaisar, T.; Aitken, M.L.; Park, D.R.; Heinecke, J.W.; Fu, X. Mapping the lung proteome in cystic fibrosis. *J. Proteome Res.* **2009**, *8*, 3020–3028. [[CrossRef](#)] [[PubMed](#)]
78. Chang, D.W.; Hayashi, S.; Gharib, S.A.; Vaisar, T.; King, S.T.; Tsuchiya, M.; Ruzinski, J.T.; Park, D.R.; Matute-Bello, G.; Wurfel, M.M.; et al. Proteomic and computational analysis of bronchoalveolar proteins during the course of the acute respiratory distress syndrome. *Am. J. Respir. Crit. Care Med.* **2008**, *178*, 701–709. [[CrossRef](#)] [[PubMed](#)]
79. Chen, J.H.; Chang, Y.W.; Yao, C.W.; Chiueh, T.S.; Huang, S.C.; Chien, K.Y.; Chen, A.; Chang, F.Y.; Wong, C.H.; Chen, Y.J. Plasma proteome of severe acute respiratory syndrome analyzed by two-dimensional gel electrophoresis and mass spectrometry. *Proc. Natl. Acad. Sci. USA* **2004**, *101*, 17039–17044. [[CrossRef](#)] [[PubMed](#)]
80. Imai, Y.; Kuba, K.; Neely, G.G.; Yaghubian-Malhami, R.; Perkmann, T.; van Loo, G.; Ermolaeva, M.; Veldhuizen, R.; Leung, Y.H.; Wang, H.; et al. Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. *Cell* **2008**, *133*, 235–249. [[CrossRef](#)] [[PubMed](#)]
81. Kolliputi, N.; Waxman, A.B. IL-6 cytoprotection in hyperoxic acute lung injury occurs via suppressor of cytokine signaling-1-induced apoptosis signal-regulating kinase-1 degradation. *Am. J. Respir. Cell Mol. Biol.* **2009**, *40*, 314–324. [[CrossRef](#)] [[PubMed](#)]
82. Conn, C.A.; McClellan, J.L.; Maassab, H.F.; Smitka, C.W.; Majde, J.A.; Kluger, M.J. Cytokines and the acute phase response to influenza virus in mice. *Am. J. Physiol.* **1995**, *268*, R78–R84. [[CrossRef](#)] [[PubMed](#)]

83. Quinton, L.J.; Jones, M.R.; Robson, B.E.; Mizgerd, J.P. Mechanisms of the hepatic acute-phase response during bacterial pneumonia. *Infect. Immun.* **2009**, *77*, 2417–2426. [[CrossRef](#)] [[PubMed](#)]
84. Brown, H.J.; Song, M.J.; Deng, H.; Wu, T.T.; Cheng, G.; Sun, R. NF-kappaB inhibits gammaherpesvirus lytic replication. *J. Virol.* **2003**, *77*, 8532–8540. [[CrossRef](#)] [[PubMed](#)]
85. Kishimoto, T.; Akira, S.; Taga, T. IL-6 receptor and mechanism of signal transduction. *Int. J. Immunopharmacol.* **1992**, *14*, 431–438. [[CrossRef](#)]
86. Lorenz, J.; Zahlten, J.; Pollok, I.; Lippmann, J.; Scharf, S.; N’Guessan, P.D.; Opitz, B.; Flieger, A.; Suttorp, N.; Hippenstiel, S.; et al. Legionella pneumophila induced IκBζ-dependent expression of IL-6 in lung epithelium. *Eur. Respir. J.* **2010**, *37*, 648–657. [[CrossRef](#)] [[PubMed](#)]
87. Breen, E.C.; Gage, J.R.; Guo, B.; Magpantay, L.; Narazaki, M.; Kishimoto, T.; Miles, S.; Martinez-Maza, O. Viral interleukin 6 stimulates human peripheral blood B cells that are unresponsive to human interleukin 6. *Cell. Immunol.* **2001**, *212*, 118–125. [[CrossRef](#)] [[PubMed](#)]
88. Deng, H.; Chu, J.T.; Rettig, M.B.; Martinez-Maza, O.; Sun, R. Rta of the human herpesvirus 8/Kaposi sarcoma-associated herpesvirus up-regulates human interleukin-6 gene expression. *Blood* **2002**, *100*, 1919–1921. [[CrossRef](#)] [[PubMed](#)]
89. Qin, Z.; Kearney, P.; Plaisance, K.; Parsons, C.H. Pivotal advance: Kaposi’s sarcoma-associated herpesvirus (KSHV)-encoded microRNA specifically induce IL-6 and IL-10 secretion by macrophages and monocytes. *J. Leukoc. Biol.* **2010**, *87*, 25–34. [[CrossRef](#)] [[PubMed](#)]
90. Cho, H.Y.; Imani, F.; Miller-DeGraff, L.; Walters, D.; Melendi, G.A.; Yamamoto, M.; Polack, F.P.; Kleeberger, S.R. Antiviral activity of Nrf2 in a murine model of respiratory syncytial virus disease. *Am. J. Respir. Crit. Care Med.* **2009**, *179*, 138–150. [[CrossRef](#)] [[PubMed](#)]
91. Choi, A.M.; Knobil, K.; Otterbein, S.L.; Eastman, D.A.; Jacoby, D.B. Oxidant stress responses in influenza virus pneumonia: Gene expression and transcription factor activation. *Am. J. Physiol.* **1996**, *271*, L383–L391. [[CrossRef](#)] [[PubMed](#)]
92. Kumar, P.; Sharma, S.; Khanna, M.; Raj, H.G. Effect of Quercetin on lipid peroxidation and changes in lung morphology in experimental influenza virus infection. *Int. J. Exp. Pathol.* **2003**, *84*, 127–133. [[CrossRef](#)] [[PubMed](#)]
93. Suliman, H.B.; Ryan, L.K.; Bishop, L.; Folz, R.J. Prevention of influenza-induced lung injury in mice overexpressing extracellular superoxide dismutase. *Am. J. Physiol. Lung Cell. Mol. Physiol.* **2001**, *280*, L69–L78. [[CrossRef](#)] [[PubMed](#)]
94. Castro, S.M.; Guerrero-Plata, A.; Suarez-Real, G.; Adegboyega, P.A.; Colasurdo, G.N.; Khan, A.M.; Garofalo, R.P.; Casola, A. Antioxidant treatment ameliorates respiratory syncytial virus-induced disease and lung inflammation. *Am. J. Respir. Crit. Care Med.* **2006**, *174*, 1361–1369. [[CrossRef](#)] [[PubMed](#)]
95. Schneider, D.; Ganesan, S.; Comstock, A.T.; Meldrum, C.A.; Mahidhara, R.; Goldsmith, A.M.; Curtis, J.L.; Martinez, F.J.; Hershenson, M.B.; Sajjan, U. Increased cytokine response of rhinovirus-infected airway epithelial cells in chronic obstructive pulmonary disease. *Am. J. Respir. Crit. Care Med.* **2010**, *182*, 332–340. [[CrossRef](#)] [[PubMed](#)]
96. Kavouras, J.H.; Prandovszky, E.; Valyi-Nagy, K.; Kovacs, S.K.; Tiwari, V.; Kovacs, M.; Shukla, D.; Valyi-Nagy, T. Herpes simplex virus type 1 infection induces oxidative stress and the release of bioactive lipid peroxidation by-products in mouse P19N neural cell cultures. *J. Neurovirol.* **2007**, *13*, 416–425. [[CrossRef](#)] [[PubMed](#)]
97. Mathew, S.S.; Bryant, P.W.; Burch, A.D. Accumulation of oxidized proteins in Herpesvirus infected cells. *Free Radic. Biol. Med.* **2010**, *49*, 383–391. [[CrossRef](#)] [[PubMed](#)]
98. Kaul, P.; Singh, I.; Turner, R.B. Effect of rhinovirus challenge on antioxidant enzymes in respiratory epithelial cells. *Free Radic. Res.* **2002**, *36*, 1085–1089. [[CrossRef](#)] [[PubMed](#)]
99. Nikolic, D.; van Breemen, R.B. DNA oxidation induced by cyclooxygenase-2. *Chem. Res. Toxicol.* **2001**, *14*, 351–354. [[CrossRef](#)] [[PubMed](#)]
100. Hartshorn, K.L. Role of surfactant protein A and D (SP-A and SP-D) in human antiviral host defense. *Front. Biosci.* **2009**, *2*, 527–546. [[CrossRef](#)]
101. Fisher, A.B.; Dodia, C.; Chander, A. Inhibition of lung calcium-independent phospholipase A2 by surfactant protein A. *Am. J. Physiol.* **1994**, *267*, L335–341. [[CrossRef](#)] [[PubMed](#)]
102. Manevich, Y.; Fisher, A.B. Peroxiredoxin 6, a 1-Cys peroxiredoxin, functions in antioxidant defense and lung phospholipid metabolism. *Free Radic. Biol. Med.* **2005**, *38*, 1422–1432. [[CrossRef](#)] [[PubMed](#)]

103. Fisher, A.B.; Dodia, C.; Yu, K.; Manevich, Y.; Feinstein, S.I. Lung phospholipid metabolism in transgenic mice overexpressing peroxiredoxin 6. *Biochim. Biophys. Acta* **2006**, *1761*, 785–792. [[CrossRef](#)] [[PubMed](#)]
104. Liu, G.; Feinstein, S.I.; Wang, Y.; Dodia, C.; Fisher, D.; Yu, K.; Ho, Y.S.; Fisher, A.B. Comparison of glutathione peroxidase 1 and peroxiredoxin 6 in protection against oxidative stress in the mouse lung. *Free Radic. Biol. Med.* **2010**, *49*, 1172–1181. [[CrossRef](#)] [[PubMed](#)]
105. Bocchino, M.; Agnese, S.; Fagone, E.; Svegliati, S.; Grieco, D.; Vancheri, C.; Gabrielli, A.; Sanduzzi, A.; Avvedimento, E.V. Reactive oxygen species are required for maintenance and differentiation of primary lung fibroblasts in idiopathic pulmonary fibrosis. *PLoS ONE* **2010**, *5*, e14003. [[CrossRef](#)] [[PubMed](#)]
106. Mazur, W.; Lindholm, P.; Vuorinen, K.; Myllarniemi, M.; Salmenkivi, K.; Kinnula, V.L. Cell-specific elevation of NRF2 and sulfiredoxin-1 as markers of oxidative stress in the lungs of idiopathic pulmonary fibrosis and non-specific interstitial pneumonia. *APMIS* **2010**, *118*, 703–712. [[CrossRef](#)] [[PubMed](#)]
107. Vuorinen, K.; Ohlmeier, S.; Lepparanta, O.; Salmenkivi, K.; Myllarniemi, M.; Kinnula, V.L. Peroxiredoxin II expression and its association with oxidative stress and cell proliferation in human idiopathic pulmonary fibrosis. *J. Histochem. Cytochem.* **2008**, *56*, 951–959. [[CrossRef](#)] [[PubMed](#)]
108. Lee, S.; Salwinski, L.; Zhang, C.; Chu, D.; Sampankanpanich, C.; Reyes, N.A.; Vangeloff, A.; Xing, F.; Li, X.; Wu, T.T.; et al. An integrated approach to elucidate the intra-viral and viral-cellular protein interaction networks of a gamma-herpesvirus. *PLoS Pathog.* **2011**, *7*, e1002297. [[CrossRef](#)] [[PubMed](#)]
109. Rodrigues, L.; Filipe, J.; Seldon, M.P.; Fonseca, L.; Anrather, J.; Soares, M.P.; Simas, J.P. Termination of NF-kappaB activity through a gammaherpesvirus protein that assembles an EC5S ubiquitin-ligase. *EMBO J.* **2009**, *28*, 1283–1295. [[CrossRef](#)] [[PubMed](#)]
110. Li, X.; Feng, J.; Sun, R. Oxidative stress induces reactivation of Kaposi's sarcoma-associated herpesvirus and death of primary effusion lymphoma cells. *J. Virol.* **2011**, *85*, 715–724. [[CrossRef](#)] [[PubMed](#)]
111. Monton, C.; Torres, A. Lung inflammatory response in pneumonia. *Monaldi Arch. Chest Dis.* **1998**, *53*, 56–63. [[PubMed](#)]
112. De Jong, H.K.; van der Poll, T.; Wiersinga, W.J. The systemic pro-inflammatory response in sepsis. *J. Innate Immun.* **2010**, *2*, 422–430. [[CrossRef](#)] [[PubMed](#)]
113. Kramer, H.B.; Lavender, K.J.; Qin, L.; Stacey, A.R.; Liu, M.K.; di Gleria, K.; Simmons, A.; Gasper-Smith, N.; Haynes, B.F.; McMichael, A.J.; et al. Elevation of intact and proteolytic fragments of acute phase proteins constitutes the earliest systemic antiviral response in HIV-1 infection. *PLoS Pathog.* **2010**, *6*, e1000893. [[CrossRef](#)] [[PubMed](#)]
114. Morgan, K.; Kalsheker, N.A. Regulation of the serine proteinase inhibitor (SERPIN) gene alpha 1-antitrypsin: A paradigm for other SERPINs. *Int. J. Biochem. Cell Biol.* **1997**, *29*, 1501–1511. [[CrossRef](#)]
115. Akira, S.; Kishimoto, T. IL-6 and NF-IL6 in acute-phase response and viral infection. *Immunol. Rev.* **1992**, *127*, 25–50. [[CrossRef](#)] [[PubMed](#)]
116. Fasnacht, N.; Muller, W. Conditional gp130 deficient mouse mutants. *Semin. Cell Dev. Biol.* **2008**, *19*, 379–384. [[CrossRef](#)] [[PubMed](#)]
117. Martinez Cordero, E.; Gonzalez, M.M.; Aguilar, L.D.; Orozco, E.H.; Hernandez Pando, R. Alpha-1-acid glycoprotein, its local production and immunopathological participation in experimental pulmonary tuberculosis. *Tuberculosis* **2008**, *88*, 203–211. [[CrossRef](#)] [[PubMed](#)]
118. Naylor, H.M.; Newcomer, M.E. The structure of human retinol-binding protein (RBP) with its carrier protein transthyretin reveals an interaction with the carboxy terminus of RBP. *Biochemistry* **1999**, *38*, 2647–2653. [[CrossRef](#)] [[PubMed](#)]

